CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$57.92 USD
+0.35 (0.61%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $58.50 +0.58 (1.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.92 USD
+0.35 (0.61%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $58.50 +0.58 (1.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Is a Beat in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
We expect CRISPR (CRSP) to provide updates on its pipeline candidates in the third quarter of 2018.
Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.
What's in Store for Sangamo (SGMO) This Earnings Season?
by Zacks Equity Research
On Sangamo's (SGMO) Q3 2018 conference call, investor focus will be on the company's progress with its genome editing and gene regulation technology platform.
Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex' (VRTX) Q3 gains on earnings and revenue beat with demand for its CF products rising high.
Alexion's (ALXN) Earnings Beat Estimates in Q3, Guidance Up
by Zacks Equity Research
Alexion (ALXN) beats earnings estimates and marginally misses sales estimates in the third quarter of 2018. The company also inks a deal to acquire Syntimmune for $1.2 billion.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.
Company News For Oct 12, 2018
by Zacks Equity Research
Companies in the news are: DAL, WBA, COST and CRSP
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
by Zacks Equity Research
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
FDA Sets Action Date for Recro's Pain Management Candidate
by Zacks Equity Research
The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain.
Bausch's Bryhali Gets Tentative FDA Nod for Plaque Psoriasis
by Zacks Equity Research
Bausch receives tentative FDA approval for the NDA for Bryhali (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients.
Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch
by Ryan McQueeney
Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.
Software and Biotech Are Eating the World
by Kevin Cook
Technology innovation is accelerating productivity, disruption and wealth creation, but what about valuations?
CRISPR THERAPTC (CRSP) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CRISPR THERAPTC (CRSP) delivered earnings and revenue surprises of -26.15% and -25.78%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) Q2 rides high on earnings and revenue beat.
Dopamine and the Weather, Part 2
by Kevin Cook
How technology changes human behavior and social rules, but not human nature and genetics???yet.
Are Options Traders Betting on a Big Move in CRISPR Therapeutics (CRSP) Stock?
by Zacks Equity Research
Investors in CRISPR Therapeutics AG (CRSP) need to pay close attention to the stock based on moves in the options market lately.
RedHill Gets Two New Patents for Crohn's Disease Candidate
by Zacks Equity Research
RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.
Nightstar Therapeutics (NITE) in Focus: Stock Moves 6.3% Higher
by Zacks Equity Research
Nightstar Therapeutics (NITE) was a big mover last session, as the company saw its shares rise more than 6% on the day.
Jazz Sells Pain Drug Prialt's Rights to TerSera Therapeutics
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) signs a definitive contract to sell its Prialt rights to TerSera Therapeutics for a settled amount of $80 million in cash upon its closure.
Pfizer's Leukemia Candidate Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants a priority review to Pfizer's (PFE) NDA for leukemia candidate glasdegib for the first-line treatment of acute myeloid leukemia (AML) in combination with chemotherapy.
Has CRISPR THERAPTC (CRSP) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CRSP) Outperforming Other Medical Stocks This Year?
Dopamine and the Weather, Part 1
by Kevin Cook
How technology changes human behavior and social rules, but not human nature and genetics---yet.
Agios Out-Licenses China Rights to Leukemia Drug Tibsovo
by Zacks Equity Research
Agios (AGIO) and CStone Pharmaceticals sign an exclusive collaboration and license agreement for the development and commercialization of its lead pipeline candidate Tibsovo.
Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia
by Zacks Equity Research
Zacks Investment Ideas feature highlights: CRISPR, Editas and Intellia
Knowledge, Certainty, and Destiny: How to Keep Up With Science & Technology
by Kevin Cook
Science is bringing the future to you faster every year and this requires a mind wide open.